Medigen Vaccine Biologics Valuation Multiples

Medigen Vaccine Biologics Overview

About Medigen Vaccine Biologics

Medigen Vaccine Biologics Corp is a biopharmaceutical company focusing on developing and producing vaccines and biologics. It is engaged in developing IP-protected cell-culture technologies for vaccine manufacturing. The company develops vaccines and affordable biosimilars to prevent regional infectious diseases. The group generates revenue from manufacturing and selling a range of COVID-19 vaccines and COVID-19 test kits and provides technical services on cellular therapy product quality and cell culture tests.

Founded

2012

HQ

Employees

129

Website

medigenvac.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $22M

EBITDA: ($686K)

EV

$455M

Valuation Multiples

Multiples.vc

Start free trial

Medigen Vaccine Biologics Financials

Medigen Vaccine Biologics reported last 12-month revenue of $22M and negative EBITDA of ($686K).

In the same LTM period, Medigen Vaccine Biologics generated $13M in gross profit, ($686K) in EBITDA losses, and had net loss of ($5M).

Medigen Vaccine Biologics P&L

In the most recent fiscal year, Medigen Vaccine Biologics reported revenue of $20M and EBITDA of ($4M).

Medigen Vaccine Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Medigen Vaccine Biologics Stock Performance

Medigen Vaccine Biologics has current market cap of $502M, and enterprise value of $455M.

Medigen Vaccine Biologics' stock price is $1.53.

Medigen Vaccine Biologics Valuation Multiples

Medigen Vaccine Biologics trades at 21.0x EV/Revenue multiple, and (663.2x) EV/EBITDA.

Medigen Vaccine Biologics Financial Valuation Multiples

As of April 19, 2026, Medigen Vaccine Biologics has market cap of $502M and EV of $455M.

Equity research analysts estimate Medigen Vaccine Biologics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Medigen Vaccine Biologics has a P/E ratio of (100.1x).

Medigen Vaccine Biologics Margins & Growth Rates

Medigen Vaccine Biologics' revenue in the last 12 month grew by 58%.

Medigen Vaccine Biologics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.

Medigen Vaccine Biologics' rule of 40 is 65% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Medigen Vaccine Biologics' rule of X is 126% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Medigen Vaccine Biologics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Medigen Vaccine Biologics M&A Activity

Medigen Vaccine Biologics acquired XXX companies to date.

Last acquisition by Medigen Vaccine Biologics was on XXXXXXXX, XXXXX. Medigen Vaccine Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Medigen Vaccine Biologics Investment Activity

Medigen Vaccine Biologics invested in XXX companies to date.

Medigen Vaccine Biologics made its latest investment on XXXXXXXX, XXXXX. Medigen Vaccine Biologics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).